MSD has announced the UK launch of Simponi (golimumab) for the treatment of adults with moderately to severely active ulcerative colitis (UC).

The new licensed medicine is indicated for patients who have not responded adequately to conventional therapy, including corticosteroids and 6-mercaptopurine, or who are intolerant to, or have contraindications for, such medicines. Golimumab is also approved for use in three other inflammatory conditions: rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.